2007, Number S2
PDF size: 90.90 Kb.
ABSTRACTMultiple drugs are helpful for rate control in different tachyarrhythmias, in particular atrial fibrillation (AF). Betablockers (bB) and calcium channel blockers have been used as monotherapy or as adjunctive therapy to antiarrhythmics for mantaining an acceptable ventricular rate. In recent years new concepts about auricular remodelation process as a consequence of AF has shown benefits with drugs as angiotensin-renin system blockers (ARSB) like angiotensin conversing enzime inhibitors (ACEI) and angiotensin receptor blockers (ARB). In this article it will be reviewed the benefits of rate control in AF by using bB and calcium channel blockers and also the benefits in atrial remodelation process and the prevention of AF with ARSB drugs.
Greenlee RT, Vidaillet H: Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol 2005; 20: 7-14.
Hagens VE, Vermeulen KM, TenVergert EM, Van Veldhuisen DJ, Bosker HA, et al: RACE study group: Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation-results for the rate control versus electrical cardioversion (RACE) study. Eur Heart J 2004, 25: 1542-1549.
Marshall D, Levy AR, Vidaillet H, Fenwick E, Slee A, et al: Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Int Med 2004; 141: 653-661.
Singh BN: b-Blockers and calcium channel blockers as antiarrhythmic drugs. Zipes, Jalife. Cardiac Electrophysiology. 4th edition 2004; 918-931.
Farshi R, Kistner D, Sarma JSM, Longmate JA, Singh BN: Ventricular rate control in chronic atrial fibrillation during daily activity and exercise by five pharmacological regimens. J Am Coll Cardiol 1999; 33: 304-310.
Tieleman RG, De Langen C, Van Gelder IC, de Kam PJ, Granjean J, et al: Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-1953.
Simone A, Stabile G, Vitale DF, Turco P, Rotunno N, et al: Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34: 810-814.
Mangano DT, Layung EL, Wallace A, Tateo I: Effect of atenolol on mortalilty and cardiovascular morbidity after non-cardiac surgery. The Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-1720.
Dunne F, Kendall MJ, Martin U: Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role? Drugs 2001; 61: 1531-1533.
Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, et al: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
Madrid AH, Peng J, Zamora J, Marin I, Bernal E, et al: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled trials. Pacing Clin Electrophysiol 2004; 27: 1405-1410.
Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, et al: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005; 45: 1832-1839.
Wachtell K, Lehto M, Gerdts E, Olsen M, Hornestam B, et al: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to Atenolol. LIFE study. J Am Coll Cardiol 2005; 45: 712-719.
Pedersen OD, Bagger H, Kfber L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, et al: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial Val-HeFT. Am Heart J 2005; 149(3): 548-557.
Ducharme A, Swedberg K, Pfeffer M, Coen-Solal A, Granger CB, et al: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 151(5): 985-91.